Cetuximab (Erbitux) is a @entity1 -mouse chimeric monoclonal antibody, which competitively binds to the accessible extracellular domain of the @entity470 ( @entity470 ) to inhibit dimerisation and, subsequently, inhibit @entity5 growth and @entity3 . In the EU and the US, cetuximab has been approved for use with concomitant radiotherapy in @entity1 with locally advanced @entity213 ( @entity213 ) and in combination with @entity2600 for the treatment of metastatic @entity14 (mCRC) in @entity1 with @entity470 -expressing @entity5 who are refractory to @entity2600 -based therapy. In the US, cetuximab has also been approved as monotherapy in @entity1 with recurrent or metastatic @entity213 for whom @entity902 -based therapy has failed and in @entity1 with mCRC who are intolerant of @entity2600 -based regimens.In treatment-naive @entity1 with locoregionally advanced @entity213 , cetuximab plus radiotherapy was more effective than radiation therapy alone in prolonging @entity66 control. In addition, more limited noncomparative data from a large trial indicated a 13% overall objective response rate (ORR) in @entity902 -refractory @entity1 with @entity213 . In @entity1 with @entity470 -expressing mCRC, cetuximab plus @entity2600 improved ORR more than cetuximab monotherapy in a trial in @entity2600 -refractory @entity1 ; however, there was no difference in @entity1349 ( @entity1349 ) between cetuximab plus @entity2600 and cetuximab monotherapy in @entity901 -refractory recipients in another trial. In an ongoing trial, progression-free survival (PFS) exceeded 50% after 12 weeks in @entity2600 -refractory @entity1 receiving three different dosages of cetuximab plus @entity2600 . In another large trial, cetuximab monotherapy prolonged @entity1349 compared with best supportive care (BSC) in heavily pretreated @entity1 . Overall, cetuximab treatment had an acceptable tolerability profile, with the majority of adverse events being mild or moderate in severity and clinically manageable. In particular, cetuximab therapy did not exacerbate @entity137 commonly associated with chemo- or radiotherapeutic regimens. Albeit occurring with high incidence, adverse cutaneous reactions appear to be a marker for response. Results of ongoing head-to-head comparative trials comparing cetuximab with other biological agents will help to establish definitively the role of cetuximab in the management of @entity213 and mCRC. In the meantime, cetuximab, with its highly targeted mechanism of action and synergistic activity with current treatment modalities, is a valuable treatment option in @entity1 with @entity213 and mCRC.

Cetuximab: a review of its use in @entity213 and metastatic XXXX .

@entity1 :: ('9606', 'Species') :: ['human', 'patients'] @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan'] @entity66 :: ('MESH:D004194', 'Disease') :: ['locoregional disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumours', 'tumour'] @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity213 :: ('MESH:C535575', 'Disease') :: ['squamous cell carcinoma of the head and neck', 'SCCHN']
@entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']
